Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Imprimer: 0893-9675
ISSN En ligne: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2014012378
pages 83-117

Drug Combinations with HDAC Inhibitors in Antitumor Therapy

Noemi Arrighetti
Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Cristina Corno
Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Laura Gatti
Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

RÉSUMÉ

The treatment of tumor cells with HDAC inhibitors (HDACi) induces a range of effects including apoptosis, cell cycle arrest, differentiation and senescence, modulation of immune response, and altered angiogenesis. The single-agent activities of several HDACi have been tested in preclinical and clinical studies and are currently the subject of ongoing clinical trials. Although HDACi have been shown to be effective as a single agent against a defined subset of hematological tumors, less convincing results have been found in the treatment of solid tumors. Since current clinical trials of single-agent HDACi showed limited efficacy, in this review we focus on drug combinations including HDACi with conventional chemotherapeutic agents and novel targeted agents. Particular emphasis has been devoted to combinations effective in solid tumors and to combinations between HDACi and immunotherapies. An outline of novel combination strategies, including a new generation of more potent and specific HDACi (e.g., compounds with adamantine and noradamantane as scaffolds) as well as chemical hybrid molecules, has been provided. The paradoxical role of HDACs as tumor suppressors in developing tumors and as therapeutic targets in established neoplasms has also been considered.


Articles with similar content:

Insight on Multidrug Resistance and Nanomedicine Approaches to Overcome MDR
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.37, 2020, issue 5
Wei He, Lifang Yin, Imran Shair Mohammad
FLT3 Signaling and the Development of Inhibitors That Target FLT3 Kinase Activity
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 2
Wallace Y. Langdon
T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy
Critical Reviews™ in Immunology, Vol.39, 2019, issue 2
David M. Kranz, Preeti Sharma
MicroRNAs as New Diagnostic and Prognostic Biomarkers in Urological Tumors
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 4
Klaus Jung, Annika Fendler
Possible Role of Epidermal Growth Factor Receptors in the Therapy of Pancreatic Cancer
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.28, 2011, issue 4
R. S. R. Murthy, Suresh P. Vyas, Manish K. Gupta, Sahil Aggarwal, Swati Gupta